Navigation Links
OHSU research highlights promising strategy to help vaccines outsmart HIV
Date:5/24/2013

PORTAND, Ore. A new discovery at Oregon Health & Science University highlights an ingenious method to ensure the body effectively reacts when infected with the highly evasive HIV virus that causes AIDS. The same team of researchers has been utilizing this unique approach to develop its own HIV vaccine candidate, which has so far shown promising results in animal studies. This latest research finding will be published in the May 24, 2013, edition of the journal Science.

"A major challenge in developing an effective HIV vaccine is figuring out how to target this evasive virus," said Dr. Louis Picker, M.D., associate director of the OHSU Vaccine and Gene Therapy Institute, where the work was conducted.

CD8+ "cytotoxic" T cells are an important component of the immune system and are particularly important for pathogens, like HIV, that easily evade antibodies. They serve as sentries within the body that detect and destroy virus-infected cells, accomplishing this function by recognizing short viral peptides on the surface of infected cells. T-cells are designed to be quite frugal in the number of different viral peptides they recognize, typically responding to just a handful of such peptides. This is a problem for control of HIV, which is able to able change its peptides and thus escape T cells responses that do not target the relatively few functionally critical peptides that can't change without debilitating the virus. In the vast majority of HIV infections, the few viral peptides recognized by T cells are not the vulnerable ones, and the virus escapes.

Therefore, the strategy that Dr. Picker and his colleagues adopted was to try to develop a vaccine to increase the number of viral peptides that T cells would recognize, reasoning that increasing this "recognition breadth" would allow T cells to more effectively respond to HIV.

The researchers found that cytomegalovirus or CMV, a common virus already carried by a large percentage of the population, may hold the key. Their studies in the non-human primate model of HIV, called SIV, found that a modified version of CMV engineered to express SIV proteins generates SIV-specific T cells that recognize three-fold as many SIV peptides as T cell generated by conventional vaccines and SIV itself. Moreover, these responses were entirely different from conventional responses, such that even viruses that had previously escaped natural responses would still be vulnerable. In effect, the hunters of the body were provided with a much better targeting system to help them find and destroy an elusive enemy.

Picker and his colleagues believe an HIV vaccine equipped with a modified CMV vector might be able to both prevent infection (prophylactic vaccine) and effectively battle the virus even if applied post-infection in individuals with infections suppressed by anti-retroviral therapy. Moving forward, the research team hopes to utilize this new information to create customized CMV vectors with a broad ability to identify several components of HIV and then incorporate this component into an effective vaccine.

"We hope we can begin clinical trials in human patients within a few years," explained Dr. Picker. "This new information gives us a much clearer roadmap for effectively targeting the disease which to this point has found ways to evade the human immune system."


'/>"/>

Contact: Jim Newman
newmanj@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Sexually abused boys at risk for more unsafe sex: UBC research
6. Researchers Find Gene Mutations That May Be a Key to Autism
7. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
8. Researchers find evidence of banned antibiotics in poultry products
9. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
10. Scientific session and new research highlights
11. NJ stroke researchers report advances in spatial neglect research at AAN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... California (PRWEB) , ... March 27, 2017 , ... The ... to its customers. First National Capital has added 10 new sales professionals over the ... its sales positions by 15 additional new hires over the course of 2017. ...
(Date:3/27/2017)... Mt. Angel, Oregon (PRWEB) , ... March 27, ... ... supplements company, is pleased to announce the launch of a months-long rebranding effort. ... exciting new formulations. , “Through focus group discussions and market research, we learned ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center ... Monday, April 3rd to commemorate the two-year anniversary of the facility. The event ... celebrate two great years while also familiarizing themselves with the facility. , In ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin Harper ... prestigious award honoring the top influencers on RealSelf—the most trusted online destination to ... and clinics. , In 2016, more than 82 million people visited RealSelf to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales forecasts in 2017, estimates ... generate $655 million in taxes on retail sales. Out of this ... Washington State,s 37% cannabis retail tax rate. ... that are applied on all retail sales. By 2020, tax revenues ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
Breaking Medicine Technology: